1	Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term
2	steroid use for the underlying disease: a multicenter, retrospective cohort study.
3	
4	Kohei Miyake ¹ *, Satoru Senoo ^{2, #a} , Ritsuya Shiiba ³ , Junko Itano ⁴ , Goro Kimura ⁴ ,
5	Tatsuyuki Kawahara ⁵ , Tomoki Tamura ⁶ , Kenichiro Kudo ⁷ , Tetsuji Kawamura ¹ ,
6	Yasuharu Nakahara ¹ , Hisao Higo ² , Daisuke Himeji ³ , Nagio Takigawa ⁵ , Nobuaki
7	Miyahara ² , and Okayama Respiratory Disease Study Group (ORDSG) ^
8	
9	¹ Department of Respiratory Medicine, National Hospital Organization Himeji Medical
10	Center, Himeji, Japan
11	Position: Medical Staff
12	² Department of Hematology, Oncology and Respiratory Medicine, Okayama University
13	Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama,
14	Japan.
15	³ Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki,
16	Japan
17	⁴ Department of Allergy and Respiratory Medicine, National Hospital Organization
18	Minami-Okayama Medical Center, Okayama, Japan
19	⁵ Department of General Internal Medicine 4, Kawasaki Medical School, Okayama,
20	Japan
21	⁶ Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical
22	Center, Iwakuni, Japan
23	⁷ Department of Respiratory Medicine, National Hospital Organization Okayama
24	Medical Center, Okayama, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 #a 26 Current Address: Department of Respiratory Medicine, National Hospital
- 26 Organization Fukuyama Medical Center, Fukuyama, Japan
- 27
- 28 *Corresponding Author: Kohei Miyake
- 29 E-mail: miyakou1723@yahoo.co.jp
- 30
- 31 ^ ORDSG is provided in the Acknowledgments.

32

33 ABSTRACT

Objective: Long-term steroid use increases the risk of developing Pneumocvstis 34 35 pneumonia (PcP), but there are limited reports on the relation of long-term steroid and 36 PcP mortality. Methods: Retrospective multicenter study to identify risk factors for PcP mortality, 37 38 including average steroid dose before the first visit for PcP in non-human 39 immunodeficiency virus (HIV)-PcP patients. We generated receiver operating 40 characteristic (ROC) curves for 90-day all-cause mortality and the mean daily steroid 41 dose per unit body weight in the preceding 10 to 90 days in 10-day increments. Patients 42 were dichotomized by 90-day mortality and propensity score-based stabilized inverse probability of treatment weighting (IPTW) adjusted covariates of age, sex, and 43 44 underlying disease. Multivariate analysis with logistic regression assessed whether long-term corticosteroid use affected outcome. 45 46 Results: Of 133 patients with non-HIV-PcP, 37 died within 90 days of initial diagnosis. The area under the ROC curve for 1-40 days was highest, and the optimal cutoff point 47 48 of median adjunctive corticosteroid dosage was 0.34 mg/kg/day. Past steroid dose, 49 underlying interstitial lung disease and emphysema, lower serum albumin and lower 50 lymphocyte count, higher lactate dehydrogenase, use of therapeutic pentamidine and 51 therapeutic high-dose steroids were all significantly associated with mortality. 52 Underlying autoimmune disease, past immunosuppressant use, and a longer time from 53 onset to start of treatment, were associated lower mortality. Logistic regression analysis 54 after adjusting for age, sex, and underlying disease with IPTW revealed that steroid 55 dose 1-40 days before the first visit for PcP (per 0.1 mg/kg/day increment, odds ratio 56 1.36 [95% confidence interval = 1.16-1.66], P<0.001), low lymphocyte counts, and high

lactate dehydrogenase revel were independent mortality risk factor, while respiratory
failure, early steroid, and sulfamethoxazole/trimethoprim for PcP treatment did not. **Conclusion:** A steroid dose before PcP onset was strongly associated with 90-day
mortality in non-HIV-PcP patients, emphasizing the importance of appropriate

62

61

63 Introduction

prophylaxis especially in this population.

64 Pneumocystis pneumonia (PcP), caused by the yeast-like fungus *Pneumocystis jirovecii*, 65 occurs primarily in immunocompromised hosts [1]. Historically, PcP was initially found in human immunodeficiency virus (HIV) patients but has increased among non-HIV 66 67 subjects in parallel with the increased use of immunosuppressive drugs including 68 corticosteroids [2-5]. PcP can lead to respiratory failure, a potentially life-threatening 69 condition; the reported mortality rate for non-HIV-PcP is higher than for HIV-70 associated PcP (HIV-PcP) [5-7]. In non-HIV-PcP, higher doses of corticosteroids are 71 reported to be the most important risk factor [3,8], and in patients with systemic 72 autoimmune diseases, higher doses of corticosteroids are reported to increase the risk of 73 developing PcP [9]. In guidelines for treating hematologic and solid tumors [10, 11], 74 primary prevention of PcP is recommended for patients with prolonged steroid use (>20 75 mg/day equivalent of prednisone for 4 weeks or ≥ 1 month). Although the efficacy of 76 sulfamethoxazole/trimethoprim (TMP-SMX) prophylaxis for the prevention of PcP is 77 well established [12-15], long-term administration of TMP-SMX can cause a variety of 78 side effects, including thrombocytopenia, toxemia, liver dysfunction, and electrolyte 79 abnormalities [16]. The therapeutic effect of corticosteroids on PcP is complex. These 80 drugs are well-established as therapy for HIV-PcP patients, blunting the inflammatory

81 response induced by anti-pneumocystis treatment, preventing respiratory

decompensation failure, and decreasing mortality [17, 18]. However, in non-HIV

- 83 patients, early addition of corticosteroids to anti-pneumocystis therapy was not
- associated with improved survival outcomes [19-26]. Furthermore, it has even been

reported that high steroid doses at diagnosis [27] or long-term pre-onset steroids [28,

86 29] were predictors of poor prognosis.

87 Corticosteroid use for underlying disease may affect mortality risk in PcP [27-30], but

studies of dose and duration that affect mortality are lacking. Details on the duration and

89 weight-corrected intensity of steroid loading are also needed, given considerations of

average body weight due to racial differences, as well as its mechanism of action in

causing late immunosuppression. We therefore studied the impact of long-term

92 corticosteroid treatment for underlying disease on mortality of PcP patients. This

retrospective observational study aimed to identify risk factors for poor prognosis in

non-HIV-PcP, with a particular focus on the weight-corrected intensity and duration of

95 corticosteroid therapy received prior to the onset of PcP.

96

97 Materials and Method

98 Study Design

99 This retrospective, multicenter observational study was conducted by the Okayama

100 Respiratory Disease Study Group. All subjects in this retrospective study were

101 Japanese. Adult patients (age 18 years and older) diagnosed with non-HIV-PcP between

102 August 1, 2010, and August 31, 2022, were included in the retrospective review of

103 medical records at seven Japanese sites. The primary endpoint of this study was 90-day

all-cause mortality, based on previous studies [21, 26, 31, 32].

- 105 The study was approved by the Institutional Ethics Committee of National Hospital
- 106 Organization Himeji Medical Center (No. 2020-28) and all other participating hospitals.
- 107 The data were analyzed anonymously. Informed consent was obtained on an opt-out
- 108 basis, and a description of the study was displayed on the websites of Himeji Medical
- 109 Center and each center. The requirement for written informed consent was waived
- 110 because of the retrospective nature of the study. The study was conducted in accordance
- 111 with the Declaration of Helsinki and all relevant Japanese laws and regulations.

112

113 **Case definition**

114 Eligible patients were defined according to their adherence to all of the following 115 selection criteria: (1) symptoms consistent with PcP (i.e., dyspnea, fever, and/or cough); 116 (2) evidence of new onset or progressive bilateral pneumonia on chest X-ray or 117 computed tomography; (3) positive Grocott staining or *P. jirovecii* DNA-specific 118 qualitative PCR (*P. jirovecii* DNA 6B614-0000-061-851, SRL, Inc., Shinjuku, Japan 119 [33]) for *P. jirovecii* cysts in respiratory specimens excluding the cases in which colony 120 formation of *P. jirovecii* was suspected during the clinical course; (4) Exclusion of 121 patients who were determined to be colonized with P. jiroveci. We considered patients 122 colonized with *P. jiroveci* if they had only positive *P. jiroveci* PCR and no pulmonary 123 symptoms, or if they had other types of infectious or autoimmune pneumonia diagnosed 124 by sputum culture, nucleic acid test, and/or antibody measurement; (5) Exclusion of 125 HIV-positive patients, and patients with insufficient data (weight, drug use data for

underlying disease, etc.). The 90-day all-cause mortality was calculated from the firstday of medical care for PcP.

128

129 Clinical data

130 Data extracted from electronic medical records included patient demographic 131 characteristics, underlying disease, previous immunosuppressive regimens for the 132 underlying disease (including corticosteroids, immunosuppressive drugs, anticancer 133 drugs, and biologics), clinical findings such as respiratory failure with a resting 134 peripheral oxygen saturation $(SpO_2) < 90$ % on admission, laboratory findings on 135 admission, anti-pneumocystis treatment regimen, and course of treatment. In addition, 136 details of all corticosteroids use during hospitalization were collected, including drug 137 name, daily dose, and duration of administration. Steroid doses were expressed in 138 prednisolone (PSL) equivalents as follows [34]: hydrocortisone, 0.25 mg PSL per mg; 139 methylprednisolone, 1.25 mg PSL per mg; betamethasone and dexamethasone, 7.5 mg 140 PSL per mg. For TMP-SMX, doses were calculated using the trimethoprim equivalent. 141 For immunosuppressants, drugs administered during 90 days prior to the first PcP visit, 142 and for administration of biologics and anticancer drugs, use or no use over the 90-day 143 period was recorded. For PcP treatment, the average daily dose of PSL per unit body 144 weight was calculated from the day of the first visit to day 5. For TMP-SMX, the 145 trimethoprim equivalent daily dose per unit body weight was tabulated, and the use or 146 lack use of atovaquone and pentamidine during the period was tabulated.

147

148 Statistical Analysis

149 Continuous variables were summarized by median interquartile range (IQR).

150 Descriptive analysis was used to examine patient characteristics. A receiver operating 151 characteristic (ROC) curve was constructed with 90 days PcP mortality as a conditional 152 variable and the mean daily steroid dose per unit body weight in the past 10 days to 90 153 days in increments of 10 days prior to the date of the first visit for PcP. The time with 154 the highest area under the ROC curve (AUC) was adopted as the period which most 155 affected mortality, and the mean steroid consumption during this period was analyzed. 156 Next, to estimate the risk of PcP mortality, we examined the average steroid dose during 157 the period of maximum AUC, as well as the use of other drugs within 30 days prior to 158 the first visit for PcP after initial diagnosis. For the PcP treatment period, the mean daily 159 dose of corticosteroid per unit body weight and TMP-SMX were calculated, divided 160 into 5 day segments; for the other drugs, only use or lack of use during the period in 161 question was considered. The outcome of interest was 90-day all-cause mortality, and 162 the γ -square test was used for testing categorical variables and the Mann-Whitney U test 163 for continuous variables to determine significant risk factors related to PcP mortality. 164 To account for the possibility of selection bias in this observational study (since the 165 intensity of corticosteroid treatment for the underlying disease was at the discretion of 166 the attending physician), we used an analysis method including stabilized treatment-167 weighted inverse probability of treatment weighting (IPTW) based on propensity scores. 168 The propensity score was defined as baseline covariates (age [21, 35-38], sex. 169 underlying disease) previously described as heightening the risk of death (hematologic 170 disease [21, 22, 31], solid organ malignancy [39, 40], and interstitial lung disease [ILD] 171 [38, 41]). Using an IPTW method with truncated stabilization weights, we reconstructed 172 a pseudo-population in which patients in both groups (90-day deceased vs. 90-day

survival) had similar characteristics balanced for age, sex, and underlying disease

174 covariates, so that outcomes could be meaningfully compared.

- 175 Adjusted data were then used to evaluate the risk of death among the 90-day survival or
- 176 mortality groups using logistic regression. Explanatory variables were included in the
- 177 propensity score model, including steroid burden for the underlying disease during the
- period of maximum AUC, days from onset to start of treatment [36, 40, 42], worsening
- respiratory status [30, 40, 43, 44], lactate dehydrogenase (LDH) [29, 40], lymphocyte
- 180 count [35, 42, 45], and early treatment with steroids, and TMP-SMX, which had
- 181 previously been implicated in increasing the risk of death. Missing values were not
- 182 complemented. EZR [46] was used for statistical analysis, and P < 0.05 was considered

183 significant.

184

185 **Result**

186 Patient Characteristics

187 During the 11-year study period, 142 patients were diagnosed with PcP at seven centers, 188 and 133 patients met the criteria and were selected for the study (Figure 1). The median 189 (IQR) age of all patients was 71.5 (64.4-78.5) years, and 49 (36.8%) were female. Total 190 mortality at 90 days after the first visit was 37 (27.8%) patients (Table 1). With the 191 exception of 3 patients, the majority (130 patients) had received immunosuppressive 192 drugs or had immunosuppressive disease at the time of diagnosis of PcP. The most 193 common underlying disease type was autoimmune (N=61), followed by solid organ 194 malignancy (N=43) and blood disease (N=24). Underlying pulmonary disease was also 195 present in 94 patients, with ILD (N=60) and emphysema (N=49) accounting for the

196 majority of cases. There were 126 patients (94.7%) with a history of

- 197 immunosuppressive or anticancer drug use in the 90 days prior to the first visit, the most
- 198 common of which was corticosteroid in 101 patients (75.9%), with a median (IQR) dose
- 199 of 0.24 (0.10-0.43) mg/kg/day. The next most common group was immunosuppressant
- 200 users (N=58), followed by anticancer drug users (N=44). Six patients received PcP
- 201 prophylaxis in the month of the first visit; one with pentamidine and the remaining five
- with TMX-SMP, but all at reduced doses than specified in the guidelines [47]. The
- 203 median (IQR) time from onset of PcP symptoms to the first visit was 4 (0-7) days; 75
- 204 patients (56.4%) had respiratory failure with $SpO_2 < 90$ % (room air) at the first visit.
- 205 Treatment consisted of antimicrobials in 130 patients (TMX-SMP in 124, atovaquone in
- 206 23, pentamidine in 18, with concomitant use), and 2 of 3 patients who did not use
- antibiotics throughout the whole course died. 24 patients did not use antibiotics on days
- 208 1-5. Corticosteroids were started or increased in 95 patients over the whole course up to
- 209 90 days after the initial visit. The median (IQR) number of days from initial visit to
- antimicrobial initiation was 1(0-3) day and the median (IQR) number of days to steroid
- 211 initiation or dose escalation was 1(0-3) day.

212 Fig 1. Patient selection flowchart



213

Table 1. Baseline Patient and Demographic Characteristics 214

	All patients		Non survivore	Suprivore	D	
	(N - 133)	N/A	(NI = 37)	(N = 06)		OR(CI)
	(N - 155)	0	(IN - 37)	(11 - 90)		
age	/1.5 (64.4-78.5)		71.4 (07.2-79.4)	/1.0 (01.0-//./)	0.255	1 20 (0 55 2 24)
	04		20	59	0.050	1.30 (0.55-3.21)
Smoking Pack Years	16.8 (0-42)	8	26.2 (0-48)	15 (0-40)	0.444	
body weight (kg)	54.0 (47.0-60.0)	0	54.7 (48.8-58.8)	53.5 (46.6-60.1)	0.798	
	159.9 (151.6-165.0)	6	159.5 (151.6-164.8)	160.0 (151.8-165.0)	0.857	
basal disease						/ _ /
autoimmune disease	61	0	11	50	0.034	0.39 (0.16-0.93)
solid organ tumor	43	0	15	28	0.294	1.65 (0.68-3.90)
hematologic disease	24	0	7	17	0.679	1.38 (0.46-3.86)
solid organ transplantation	4	0	0	4	0.506	0.00 (0.00-3.94)
interstitial lung disease	60	0	23	37	0.024	2.60 (1.12-6.21)
asthma	2	0	0	2	0.929	0.00 (0.00-13.9)
basal lung CT findings						
bronchiectasis	17	1	6	11	0.560	1.54 (0.43-5.03)
emphysema	49	1	20	29	0.013	2.86 (1.22-6.86)
honeycomb lung	14	1	4	10	1.000	1.07 (0.23-4.31)
traction bronchiectasis	44	1	17	27	0.062	2.27 (0.96-5.41)
chronic immunosuppressive regimen						
basal corticosteroid dose						
1-30 day ^b	0.126 (0.035-0.377)	0	0.412 (0.253-0.618)	0.096 (0.000-0.193)	<0.001	
1-60 day ^b	0.123 (0.050-0.380)	0	0.421 (0.281-0.629)	0.097 (0.095-0.218)	<0.001	
1-40 day ^b	0.119 (0.039-0.393)	0	0.425 (0.336-0.695)	0.093 (0.000-0.183)	<0.001	
basal immunosuppressive regimen						
immunosuppressant	58	0	10	48	0.028	0.37 (0.14-0.90)
MTX	39	0	3	36	0.002	0.15 (0.03-0.53)
CNI	19	0	6	13	0.906	1.23 (0.35-3.87)
orther immunosuppuressant	9	0	4	5	0.443	2.19 (0.41-10.9)
biologic agent	7	0	0	7	0.210	0.00 (0.00-1.77)
anticancer drug	44	0	14	30	0.604	1.34 (0.55-3.16)
PcP prophylaxis	6	0	4	2	0.088	5.61 (0.76-64.8)
onset to first touch (days)	4 (0-7)	0	2 (1-5)	5 (0-9)	0.062	
hypoxia	75	0	29	46	0.003	3.90 (1.54-10.9)
laboratory data						
(1→3) β-D-glucan ^c (pg/mL)	31.3 (10.9-98.8)	1	41.0 (15.7-141.8)	27.6 (10.5-67.3)	0.258	
serum albumin (g/dL)	2.9 (2.4-3.3)	38	2.6 (2.3-3.2)	3.0 (2.6-3.5)	0.027	
CRP (mg/dL)	6.97 (4.03-11.46)	0	6.59 (4.51-13.4)	6.99 (3.73-10.8)	0.825	
KL-6 (U/mL)	603 (370-970)	17	827 (556-1645)	534 (362-793)	0.001	
LDH (IU/L)	330 (273-450)	0	363 (310-538)	326 (268-420)	0.015	
lymphocyte count (mm ³)	650 (377-1,070)	0	460 (317-680)	720 (411-1185)	0.004	
SP-D (ng/mL)	147 (93-239)	57	236 (146-312)	137 (78-223)	0.027	
white blood cell count (mm ³)	8700 (6200-11000)	0	7960 (5600-9400)	8750 (6625-11723)	0.060	
PcP therapy time days				, , , , , , , , , , , , , , , , , , ,		
onset to anti PcP drug initiation	6 (2-12)	3	3 (2-8)	7 (4-14)	0.005	
onset to steroid dose-up or initiation	6 (2-11)	38	2 (2-7)	7 (3-11)	0.012	
first visit to anti-PcP drug initiation	1 (0-3)	3	1 (0-2)	1 (0-4)	0.184	
first visit to steroid dose-up or initiation	1 (0-3)	38	1 (0-2)	1 (0-3)	0.604	
PcP therapy	(***/					
corticosteroid dose for 1-5dav**	0.804 (0.122-8.001)	0	2.441 (0.535-11.67)	0.603 (0.078-6.653)	0.015	
TMP-SMX use for day 1-5	100	0	26	74	0.554	0.70 (0.28-1.84)
TMP-SMX dose for 1-5dav**	5.858 (0.292-10 505)	0	4.683 (0.000-10 105)	5,998 (0,854-10,936)	0.549	
atovaguone use for day 1-5	6	0	2	4	1.000	1.31 (0.11-9.62)
pentamidine use for day 1-5	8		- 7	1	<0.001	21 6 (2 61-103)
first visit to last follow days	124 (24-954)	0	17 (8-32)	422 (96-1357)	0.001	

 $[\]begin{array}{c} 215 \\ 216 \\ 217 \\ 218 \\ 219 \\ 220 \\ 221 \\ 222 \end{array}$

CI: confidence interval; NA: not available; OR: odds ratio,

Continuous variables were expressed as median (IQR), and nominal variables were expressed as number of cases.

^a Mann-Whitney U or χ-square test

^b mg/kg/day

° (122 patients underwent test WAKO (FUJIFILM Wako Pure Chemical Corp.) or 11 patients underwent Fungitec G Test

MK II (NISSUI BG))

223

224 ROC curves for corticosteroid dosage

- 225 The AUCs of each ROC curve constructed with the mean daily corticosteroid use per
- unit body weight and 90-day mortality in the past 10 days to 90 days in increments of
- 10 days are shown in Table 2. The AUC was the highest for the past 1-40 days for 90-
- day mortality (0.8305, 95% confidence interval [CI] 0.7404-0.9206), and the distance-
- to-the-corner method indicated a cutoff value of mean corticosteroid dose of 0.34
- 230 mg/kg/day (Figure 2). Indeed, the mortality by dose category of cumulative steroid dose
- in the past 1-40 days, mortality was significantly higher above 0.3 mg/kg/day (Table 3,
- 232 Figure 3).
- 233 Table 2. AUC of ROC curve of increments of 10 days median corticosteroid dose
- for underlying disease in predicting 90-day all-cause mortality in patients with

235 **Pneumocystis pneumonia by period before the first visit.**

	AUC
1-10 day	0.800
1-20 day	0.793
1-30 day	0.815
1-40 day	0.824
1-50 day	0.818
1-60 day	0.795
1-70 day	0.778
1-80 day	0.773
1-90 day	0.769

236

Fig 2. ROC/AUC analysis. ROC curve analysis showing the performance of past 40
 days corticosteroid dose before PcP first visit in predicting all-cause 90-day mortality of

239 non-HIV-PcP patients.



Fig 3. 90-day mortality by category of mean steroid load 1-40 days before first 241

242 visit.



Table 3. 90-day mortality by dose category of cumulative steroid dose

1-40day corticosteroid dose	Ν	OR (95%CI)	P value
<0.1 ª	57	Reference	Reference
0.1-0.2ª	24	1.49 (0.33-6.78)	0.609
0.2-0.3ª	6	2.08 (0.20-21.5)	0.539
0.3-0.4 ª	14	5.78 (1.39-24.1)	0.016
0.4-0.5ª	14	18.7 (4.49-78)	<0.001
≥0.5 ª	18	36.4 (8.61-54)	<0.001

245 a mg/kg/day

246 CI: confidence interval; OR: odds ratio

247

243

248 Comparison of survivors vs. non-survivors

A comparison of survivors (N=96) and non-survivors (N=37) is shown in Table 1.

- 250 There were no significant differences in age and gender between the two groups. In
- terms of underlying disease, solid organ malignancies were significantly more common

252 in the deceased patients, while autoimmune diseases were less common. Of the 253 underlying pulmonary diseases, ILD and emphysema were significantly more common 254 in the deceased patients with CT findings. Regarding medications for underlying 255 disease, baseline corticosteroid daily doses per unit body weight for 30 and 60 days 256 before the PcP first visit were significantly higher in the deceased patient group than in 257 the survivors. Among immunosuppressive drugs, methotrexate (MTX) was used for 258 significantly fewer patients in the deceased group, but no difference was seen for 259 anticancer drugs. Respiratory failure was associated with a worse prognosis. Laboratory 260 values of LDH, Krebs von den Lungen-6 (KL-6), and pulmonary surfactant protein-D 261 (SP-D) were significantly higher in the deceased patients, and serum albumin (Alb) and 262 lymphocyte counts were significantly lower. The time from disease onset to the first 263 medical examination was significantly shorter for the patients who died, and the days 264 from disease onset to the start of treatment were also significantly fewer, and more 265 deceased patients had progressed rapidly. In terms of treatment, the initial steroid dose 266 of day 1-5 was significantly higher in the deceased group, but there was no significant 267 difference in the fixed dose of TMX-SMP between survivors and non-survivors. 268 Characteristics before and after the weighting process are shown in Table 4. In a 269 multivariate analysis adjusted for propensity score reciprocal weighting, initial 270 therapeutic steroid dose and the fixed-dose combination were not significant markers, 271 but mean steroid dose prior to PcP first day (per 0.1 mg/kg/day increment, odds ratio 272 1.36 [95% CI = 1.16-1.66], P < 0.001), cumulative steroid dose, LDH, and lymphocyte count were significant predictors of mortality (Table 5). 273

274 Table 4. Propensity score-based stabilized treatment-weighted inverse probability

275 inverse probability (IPTW) to adjust for the covariates age, sex and underlying

276 disease.

mortality	Unweighted			IPTW-weighted		
Factor	Nonsurvivors	Survivors	SMD	Nonsurvivors	Survivors	SMD
	37	96		34.9	96.8	
Age (range)	71.4 (46.8-90.0)	71.6 (18.2-90.2)	0.343	70.9 (46.8-90.0)	72.2 (18.2-90.2)	0.110
Sex M (%)	25 (67.6)	59 (61.5)	0.128	22.5 (64.5)	61.8 (63.8)	0.014
F (%)	12 (30.6)	37 (38.5)		12.4 (35.5)	35.0 (36.2)	
Based disease						
blood disease (%)	8 (21.6)	16 (16.7)	0.126	7.9 (22.7)	18.7 (19.3)	0.085
ILD (%)	23 (62.2)	37 (38.5)	0.486	17.0 (48.8)	44.3 (45.8)	0.061
Solid organ tumor (%)	15 (40.5)	28 (29.2)	0.240	11.8 (33.9)	31.6 (32.6)	0.028

277 ILD: interstitial lung disease; SMD: standardized mean difference

278 Table 5. Multivariate logistic regression analysis

	Unadjusted		Propensity weighte	d
	OR (95% CI)	P value	OR (95% CI)	P value
Corticosteroid for based disease 1-40day ^a	1.36 (1.15-1.60)	<0.001	1.39 (1.16-1.66)	<0.001
Onset to First visit	0.96 (0.89-1.05)	0.405	0.97 (0.90-1.06)	0.539
Lactate dehydrogenase ^b	1.44 (1.06-1.97)	0.021	1.37 (0.90-1.88)	0.049
Lymphocyte count °	0.89 (0.80-0.98)	0.024	0.88 (0.78-0.98)	0.023
Нурохіа	2.07 (0.64-6.73)	0.228	1.76 (0.54-5.67)	0.347
Corticosteroid for PcP therapy 1-5day ^d	1.03 (0.96-1.11)	0.429	1.03 (0.95-1.12)	0.442
TMP-SMX for PcP therapy 1-5day ^d	0.93 (0.84-1.02)	0.108	0.93 (0.85-1.02)	0.143

279 CI: confidence interval; OR: odds ration;

280 a per 0.1 mg/kg/day increment

281 ^b per 100 U/L increment

282 ° per 100/mm³ increment

- 283 d per 1mg/kg/day increment
- 284

Discussion 285

286 In this retrospective study, we found that a corticosteroid dose before PcP onset had

287 significant negative impact on 90-day all-cause mortality. Long-term corticosteroid

288 loading for underlying disease increased the mortality of PcP in a dose-dependent 289 manner. Furthermore, in multivariate analysis, long-term steroid loading before PcP 290 onset significantly affected 90-day mortality, while respiratory failure, early steroid and 291 TMP-SMX for PcP treatment did not. Pre-onset long-term steroid loading had the 292 greatest impact. Although there is some doubt about the validity of calculating 293 statistically daily, the AUC was maximized (0.8314) for the past 7-39 days. This 294 suggests that corticosteroid loading in the more distant past than just before the onset of 295 PcP has a greater impact on the mortality rate of PcP. Prior studies had shown that 296 corticosteroids for underlying disease have an impact on the mortality of PcP [27-30]. 297 Here, we report that baseline steroid loading was more strongly associated with the 298 mortality of PcP than hypoxemia at the initiation of treatment or the corticosteroid and 299 antibiotic treatment given for PcP. This suggests that proper risk assessment and 300 appropriate prophylaxis in high-risk patients is more important for PcP than early 301 detection and treatment. However, in the present study, patients who developed PcP 302 despite prophylaxis was not good prognosis, so further investigation is needed on the 303 intensity and duration of such prophylaxis. 304 In this study, we found that the prognostic impact of antimicrobials and steroids on

305 treatment of non-HIV-PcP was less than that of corticosteroids for underlying disease.

306 Three patients did not receive any antimicrobial therapy, but two of them died (the

307 remaining patient resolved spontaneously; this was a patient with no underlying

308 immunosuppressive disease). It is not unusual for eligible patients to have occult

309 infection [48], but there are several reports of cases where eligible persons developed

310 PcP [48-51], which generally has a poor prognosis. However, there are also reports of

311 patients recovering without complications [50]. On the other hand, we report four cases

of death without a history of steroid use. All cases had underlying hematologic disease 312 313 (malignant lymphoma, aplastic anemia, myelofibrosis, and myelodysplastic syndrome). 314 A longer the period from onset to treatment initiation was proportionally associated with a better prognosis. This may because many of the patients who started treatment 315 316 early had rapid deterioration and respiratory failure, resulting in a poor prognosis. This 317 suggests that immunity before disease onset has a greater impact on prognosis, 318 suggesting that prevention is of paramount importance. 319 No treatment guidelines have been released for non-HIV-PcP, but this may be due to the 320 diversity of patients' immune status. It is known that alveolar macrophages and CD4-321 positive T cells, play a major role in immunity against PcP [52]. Corticosteroids 322 interfere with many pathways within the immune system and reduce the number and 323 function of peripheral blood CD4-positive lymphocytes, clearly associated with a 324 significant risk of PcP in non-HIV patients [53]. Corticosteroids have further been 325 shown to impair alveolar macrophage function [54]. In a dexamethasone-induced 326 immunosuppression model in rats, macrophages were found to be deficient in nitric 327 oxide and hydrogen peroxide production even in Pc infection [55, 56], suggesting that 328 the bactericidal capacity of Pneumocystis is problematic. These results may explain the 329 poor prognosis of PcP associated with long-term steroid accumulation. 330 The current study has several limitations. Because of its retrospective nature, the 331 diagnosis and treatment of PcP was not standardized; diagnosis was made using either 332 only staining, PCR results or classical clinical criteria. Because PCR for PcP is not 333 covered by healthcare insurance in Japan, many cases of suspected PcP were diagnosed 334 by imaging and clinical findings of PcP based on cutoffs for $(1\rightarrow 3)\beta$ -D-glucan 335 elevation [57, 58], and many cases were likely missed. We also had to exclude cases

where estimated steroid use in the past 90 days could not be assessed and cases with no 336 337 history of weight measurement, which may have affected our results due to selection 338 bias. Also, only a rough assessment of respiratory impairment was possible. 339 Additionally, too low a number of cases resulted in a situation where logistic regression 340 analysis resulted in an overabundance of explanatory variables and insufficient test power. In the present study, it was impossible to determine whether continuous or 341 342 intermittent dosing was riskier because it was not possible to distinguish whether daily 343 dosing was pulsatile or continuous. Finally, Alb test data, which had been reported to 344 contribute to PcP prognosis in previous studies, could not be evaluated due to the large 345 number of missing values. Prospective studies and a larger number of cases must be 346 considered in the future.

347

348 Conclusions

349 In this propensity-matched cohort study, we found that corticosteroid administration in

the 40-day period before the onset of PcP increased the mortality in a dose-dependent

351 manner (per 0.1 mg/kg/day increment, odds ratio $1.36 [95\% \text{ CI} = 1.16 \cdot 1.66]$, P < 0.001).

352 Thus, long-term corticosteroid loading for treating the underlying disease strongly

affects the prognosis of PcP, emphasizing the importance of appropriate prophylaxisespecially in this population.

355

356 Acknowledgments

We thank to Okayama Respiratory Disease Study Group for providing the case data.

359 **Reference**

- 1. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350: 2487–
- 361 **2498**.
- 362 2. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis
- 363 carinii pneumonia among patients without AIDS at a cancer hospital.
- 364 JAMA. 1992;267: 832-837.
- 365 3. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired
- 366 immunodeficiency syndrome: associated illness and prior corticosteroid therapy.
- 367 Mayo Clin Proc. 1996;71: 5-13.
- 4. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients
- 369 without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern
- 370 Med. 1995;155: 2436-2441.
- 371 5. Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S.
- 372 Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J
- 373 Infect Dis. 2016;46: 11-17.
- 6. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome
- patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of
- 376 HIV-associated cases to other immunocompromised states. Chest. 2000;118: 704-
- 377 711.
- 378 7. Roux A, Canet E, Valade S, Robert FG, Hamane S, Lafabrie A, et al. Pneumocystis
- 379 jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect
- 380 Dis. 2014;20: 1490-1497.

381	8. Roblot F, Moal GL, Kufmann-Lacroix C, Bastides F, Boutlille D, Verdon R, et
382	al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study
383	with focus on immunosuppressive drugs and markers of immune impairment. Scand
384	J Infect Dis. 2014;46: 210-214.
385	9. Aoki Y, Iwamoto M, Kamata Y, Nagashima T, Yoshio T, Okazaki H, et al.
386	Prognostic indicators related to death in patients with Pneumocystis pneumonia
387	associated with collagen vascular diseases. Rheumatol Int. 2009;29: 1327-1330.
388	10. Classen AY, Henze L, Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff LD,
389	et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii
390	pneumonia in patients with hematologic malignancies and solid tumors: 2020
391	updated guidelines of the Infectious Diseases Working Party of the German Society
392	of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol. 2021;100:
393	1603-1620.
394	11. Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial Prophylaxis for Adult
395	Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical
396	Practice Guideline Update Summary J Oncol Pract. 2018;14: 692-695.
397	12. Ioannidis JP, Cappelleri J, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the
398	relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch
399	Intern Med. 1996;156: 177-188.
400	13. Neofytos N, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller N, et al.
401	Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive
402	analysis for the Swiss Transplant Cohort. Transpl Infect Dis. 2018;20: e12984.
403	14. Park JW, Curtis JR, Kim MJ, Lee H, Song YW, Lee EB. Pneumocystis pneumonia
404	in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-

- 405 clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
- 406 Arthritis Res Ther. 2019;21: 207.
- 407 15. Miyake K, Kawamura T, Nakahara Y, Sasaki S. A single-center, person-month-
- 408 based analysis of the risk of developing Pneumocystis pneumonia (PCP) in
- 409 immunosuppressed non-HIV patients: Preventive effects of trimethoprim-
- 410 sulfamethoxazole. J Infect Chemother. 2023;S1341-321X(23)00174-5. doi:
- 411 10.1016/j.jiac.2023.07.012.
- 412 16. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis
- 413 pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database
- 414 Syst Rev. 2014;10: CD005590.
- 415 17. Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive corticosteroids for
- 416 Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database
- 417 Syst Rev. 2006;3: CD006150.
- 418 18. Ewald H, Raatx H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive
- 419 corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection.
- 420 Cochrane Database Syst Rev. 2015;4: CD006150.
- 421 19. Pareja JG, Garland r, Koziel H. Use of adjunctive corticosteroids in severe adult
- 422 non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113: 1215-1224.
- 423 20. Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L, et al.
- 424 Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in
- 425 non-human immunodeficiency virus-infected patients: retrospective study of 31
- 426 patients. Clin Infect Dis. 1999;29: 670-672.

427 21. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH, et al. Outcomes of

- 428 moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-
- 429 HIV-infected patients. Antimicrob Agents Chemother. 2011;55: 4613-4618.
- 430 22. Lemiale V, Debrumets A, Delonnoy A, Alberti C, Azoulay E. Adjunctive steroid in
- 431 HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14:
- 432 87.
- 433 23. Injean P, Eells SJ, Wu H, McElroy I, Gregson AL, McKinnel JA. A Systematic
- 434 Review and Meta-Analysis of the Data Behind Current Recommendations for
- 435 Corticosteroids in Non-HIV-Related PCP: Knowing When You Are on Shaky
- 436 Foundations. Transplant Direct. 2017;3: e137.
- 437 24. Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA, et
- 438 al. Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are

439 Not Associated With Better Outcome. Chest. 2018;154: 636-644.

- 440 25. Assal M, Lambert J, Chow-Chine L, Bisbal M, Servan L, Gonzalez F, et al.
- 441 Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or
- haematology patients with Pneumocystis jirovecii pneumonia: A propensity score
- 443 analysis. *PLoS One*. 2021;16: e0250611.
- 444 26. Huang YM, Lu CH, Cheng CF, Shen CY, Hsieh SC, Li KJ, et al. Clinical features
- and prognostic predictors in patients with rheumatic diseases complicated by
- Pneumocystis pneumonia. Int J Infect Dis. 2022;122: 1018-1025.
- 447 27. Ando T, Abe Y, Endo Y Tada K, Yamaji K, Tamura N. Rapid glucocorticoid
- tapering therapy to reduce mortality from pneumocystis pneumonia in patients with
- rheumatic disease. Mod Rheumatol. 2019;29: 656-666.

450	28. Pagano L, Fianchi L, M	lele L, Girmenia C, Offidani	M, Ricci P, et al. Pneumocystis

- 451 carinii pneumonia in patients with malignant haematological diseases: 10 years'
- 452 experience of infection in GIMEMA centres. Br J Haematol. 2002;117: 379-386.
- 453 29. Roblot F, Moal GL, Godet C, Hutin P, Texereau M, Boyer E, et al. Pneumocystis
- 454 carinii pneumonia in patients with hematologic malignancies: a descriptive study. J
- 455 Infect. 2003;47: 19-27.
- 456 30. Chen M, Tian X, Qin F, Zhou J, Liu J, Wang M, et al. Pneumocystis Pneumonia in
- 457 Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical
- 458 Characteristics and Prognostic Factors Related to Death. *PLoS One. 2015* Sep 30;10:
- 459 e0139144.
- 460 31. Kim T, Moon SM, Sung H, Kim MN, Kim SH, Choi SH, et al. Outcomes of non-
- 461 HIV-infected patients with Pneumocystis pneumonia and concomitant pulmonary

462 cytomegalovirus infection. Scand J Infect Dis. 2012;44: 670-677.

- 463 32. Gaborit BJ, Tessoulin B, Lavergne RA, Morio F, Sagan C, Canet E, et al. Outcome
- and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised
- adults: a prospective observational study. Ann Intensive Care. 2019;9: 131.
- 466 33. Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, Moxon ER, et al.
- 467 Detection of Pneumocystis carinii with DNA amplification. Lancet 1990;336: 451-3.
- 468 34. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A
- 469 practical guide to the monitoring and management of the complications of systemic
- 470 corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9: 30.
- 471 35. Kageyama T, Furuta S, Ikeda K, Kagami S, Kashiwakura D, Sugiyama T, et al.
- 472 Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune
- 473 diseases. PLoS One. 2019;14: e0214324.

474	36. Ko RE, Na SJ, Huh K, Suh GY, Jeon K. Association of time-to-treatment with
475	outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative
476	patients. Respir Res. 2019;20: 213.
477	37. Verhaert M, Blockmans D, Langhe ED, Henckaerts L. Pneumocystis jirovecii
478	pneumonia in patients treated for systemic autoimmune disorders: a retrospective
479	analysis of patient characteristics and outcome. Scand J Rheumatol. 2020;49: 345-
480	352.
481	38. Ishikawa Y, Nakano K, Tokutsu K, Miyata H, Fujino Y, Matsuda S, et al.
482	Estimation of treatment and prognostic factors of pneumocystis pneumonia in
483	patients with connective tissue diseases. RMD Open. 2021 Mar;7: e001508.
484	39. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE,
485	et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis
486	jirovecii pneumonia in HIV-negative patients. J Infect Chemother. 2014;20: 412-416.
487	40. Liu Y, Su L, Jiang SJ, Qu H. Risk factors for mortality from pneumocystis carinii
488	pneumonia (PCP) in non-HIV patients: a meta-analysis. Oncotarget. 2017;8: 59729-
489	59739
490	41. Hamada S, Ichiyasu H, Inaba M, Takahashi H, Sadamatsu T, Akaike K, et al.
491	Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with
492	Pneumocystis pneumonia. ERJ Open Res. 2020;6: 00306-2019.
493	42. Li MC, Lee NY, Lee HC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci
494	pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes
495	in non-HIV-infected individuals. J Microbiol Immunol Infect. 2014;47: 42-47.

- 496 43. Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, et al. Prognostic factors of
- 497 Pneumocystis jirovecii pneumonia in patients without HIV infection. J
- 498 Infect. 2014;69: 88-95
- 499 44. Choi JS, Lee SH, Leem AY, Song JH, Kim SY, Chung KS, et al. Pneumocystis
- 500 jirovecii pneumonia (PCP) PCR-negative conversion predicts prognosis of HIV-
- negative patients with PCP and acute respiratory failure. *PLoS One*. 2018;13:
- 502 e0206231.
- 45. Cao Y, Chen J, Dong L. Supplementary Role of Immunological Indicators in the
- 504 Diagnosis and Prognosis of Pneumocystis Pneumonia in Non-HIV
- 505 Immunocompromised Patients. Infect Drug Resist. 2022;15: 4675-4683.
- 506 46. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for

507 medical statistics. Bone Marrow Transplant. 2013;48: 452-458.

- 508 47. cdc.gov [Internet]. Guidelines for Prevention and Treatment of Opportunistic
- 509 Infections in HIV-Infected Adults and Adolescents [cited 2015 Sep 7]; Available
- 510 from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm
- 511 48. Jacobs JL, Libby DM, Winters RA, Gelmont DM, Fried ED, Hartman BJ, et al. A
- 512 cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N
- 513 Engl J Med. 1991;324: 246-250.
- 49. Cano S, Capote F, Calderon E, Castillo J. Pneumocystis carinii pneumonia in
- 515 patients without predisposing illnesses. Acute episode and follow-up of five cases.
- 516 Chest. 1993;104: 376-381.
- 517 50. Harris K, Maroun R, Chalhoub M, Elsayegh D. Unusual presentation of
- 518 pneumocystis pneumonia in an immunocompetent patient diagnosed by open lung
- 519 biopsy. Heart Lung Circ. 2012;21 :221-224.

- 520 51. Ide H, Yamaji Y, Tobino K, Okahisa M, Murakami K, Goto Y, et al. Pneumocystis
- 521 jirovecii Pneumonia in an Immunocompetent Japanese Man: A Case Report and
- 522 Literature Review. Case Rep Pulmonol. 2019;2019: 3981681.
- 523 52. Otieno-Odhiambo P, Wasseriman S, Hoving JC. The Contribution of Host Cells to
- 524 Pneumocystis Immunity: An Update. Pathogens. 2019;8: 52.
- 525 53. Iriart X, Bouar ML, Kamar N, Berry A. Pneumocystis Pneumonia in Solid-Organ
- 526 Transplant Recipients. J Fungi (Basel). 2015;1: 293-331.
- 527 54. Schaffner A, Schaffner T. Glucocorticoid-induced impairment of macrophage
- antimicrobial activity: mechanisms and dependence on the state of activation. Rev
- 529 Infect Dis. 1987;S5: S620-9.
- 530 55. Lasbury ME, Liao CP, Hage CA, Durant PJ, Tschang D, Wang SH, et al. Defective
- nitric oxide production by alveolar macrophages during Pneumocystis pneumonia.

532 Am J Respir Cell Mol Biol. 2011;44: 540-547.

- 533 56. Nandakumar V, Hebrink D, Jenson P, Kottom T, Limper AH. Differential
- 534 Macrophage Polarization from Pneumocystis in Immunocompetent and
- 535 Immunosuppressed Hosts: Potential Adjunctive Therapy during Pneumonia. Infect
- 536 *Immun.* 2017;85: e00939-16.
- 537 57. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al.
- 538 Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;121:
- 539 1173-1180
- 540 58. Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukada K, et al. Serum
- 541 (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of
- 542 Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49: 1128-
- 543 1131.